Arginine glutamate
Also known as: Arginine glutamate salt, Arginini glutamas, Glutargin, L-Arginine L-Glutamate
Source Arginine glutamate at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Arginine glutamate is an approved prescription amino‑acid salt composed of L‑arginine and L‑glutamate. It is supplied for intravenous or oral use and is investigated chiefly for supporting liver‑related metabolic disorders such as mild hepatic encephalopathy, where it may help lower blood ammonia and improve neurological function.
Mechanism of Action
The compound provides arginine, a substrate for nitric oxide synthase that generates nitric oxide, a vasodilator and signalling molecule, and glutamate, a key excitatory neurotransmitter and precursor for glutathione. Together they contribute to nitrogen handling, supporting the urea cycle and ammonia detoxification, and may influence vascular and neural pathways implicated in liver‑brain dysfunction.
What the Research Shows
Evidence for arginine glutamate comes from a range of sources. A 2019 review highlighted arginine and glutamate as beneficial amino acids for intestinal development in weaned piglets, suggesting a role in gut health. A 2023 cellular review linked arginine and glutamate metabolism to lipid synthesis in nitrogen‑deprived algae, underscoring their broader metabolic relevance. A 2025 cardiovascular review described arginine‑derived nitric oxide as modulatory in coronary disease, while glutamate dysregulation was noted as harmful. The most direct clinical data are from a 2025 open‑label, non‑inferiority randomised trial in 108 cirrhotic patients with mild hepatic encephalopathy, where intravenous arginine glutamate achieved clinical improvement in 88.9% of participants, comparable to L‑ornithine‑L‑aspartate, and produced similar reductions in blood ammonia.
Reported Benefits
In the hepatic encephalopathy trial, arginine glutamate was non‑inferior to the standard therapy L‑ornithine‑L‑aspartate, yielding comparable rates of symptom improvement, ammonia reduction, and faster performance on neurocognitive testing. Review literature also suggests potential benefits for intestinal mucosal development in young animals and for nitric‑oxide‑mediated vascular effects in heart disease, although these are not yet demonstrated in humans.
Limitations of the Evidence
Clinical evidence is limited to a single, open‑label, single‑centre trial involving only mild hepatic encephalopathy and a short 7‑day treatment period; blinding and larger multicentre confirmation are lacking. Benefits for gut health or cardiovascular outcomes are inferred from animal studies and mechanistic reviews, not from controlled human trials. The overall safety profile beyond the trial’s short follow‑up remains under‑characterised.
Safety Considerations
The hepatic encephalopathy study reported adverse events in a similar proportion to the comparator, with only four cases identified as drug‑related reactions, suggesting a tolerable short‑term safety profile. No serious safety signals were described in the available literature, but comprehensive long‑term safety data are absent, and caution is advised in patients with severe liver dysfunction or electrolyte disturbances.
How It Is Administered
Arginine glutamate is formulated for intravenous injection, as used in the hepatic encephalopathy trial, and is also available in oral formulations. Dosing regimens, concentrations, and duration of therapy are defined by prescribing information and clinical judgment; the compound is administered under medical supervision.
Routes of Administration
Goals & Uses
- Nitrogen balance supportNutritional SupportLow
- Liver protection / hepatoprotectionHepatologyLow
- Hepatic encephalopathy managementHepatologyModerate
- Nitric oxide precursor supportCardiovascularLow
- Ammonia detoxificationMetabolic SupportModerate
Contraindications
- Severe renal failureRenal ImpairmentHigh
- Severe metabolic alkalosisElectrolyte/acid Base DisorderModerate
- HyperargininemiaMetabolic DisorderHigh
- Known hypersensitivity to arginine or glutamateAllergyHigh
Adverse Effects
- Injection site reactionsLocalUncommon
- HypotensionCardiovascularUncommonLow blood pressure
- FlushingVascularUncommonWarmth and redness of the skin
- Nausea and vomitingGastrointestinalCommon
- HyperkalemiaElectrolyte ImbalanceUncommon
Drug Interactions
- Antihypertensive agentsLow
- Potassium-sparing diuretics / ACE inhibitorsModerate
- Lysine supplementsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Patients with active herpes simplex infectionInfectious DiseaseRelative
Regulatory Status
- European UnionApprovedApproved: Hepatic encephalopathy, Hyperammonemia supportApproved in some EU member states (e.g., Ukraine, Romania) as a pharmaceutical; not centrally approved by EMA.
- United StatesUnapprovedNot FDA-approved as a drug. Constituent amino acids are available as dietary supplements (GRAS status).
- United KingdomUnknownNo specific MHRA approval identified for arginine glutamate as a pharmaceutical entity.
Approved in several European and Asian countries as a parenteral or oral hepatoprotective agent. Not independently FDA-approved in the United States as a drug, though its constituent amino acids are GRAS. Available as a pharmaceutical product (e.g., Glutargin) in Ukraine and some Eastern European countries.
Evidence & Sources
- Journal ArticleModerateMou Q, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleModerateMonteiro LFR, Giraldi LA, Winck FV2023-01-01T00:00:00.000000Z
- Journal ArticleModerateShen R, Zhang Y2025-01-01T00:00:00.000000Z
- Journal ArticleModerateZhang HB, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateSpiegel JO, Van Houten B, Durrant JD2021-01-01T00:00:00.000000Z
- Journal ArticleHighCao SL, et al.2018-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition has arginine glutamate been tested for in humans?
A single open‑label randomised trial evaluated intravenous arginine glutamate for mild hepatic encephalopathy in cirrhotic patients, finding it non‑inferior to L‑ornithine‑L‑aspartate in improving symptoms and lowering blood ammonia.
How does arginine glutamate potentially work in liver disease?
The salt supplies arginine, which can be converted to nitric oxide and supports the urea cycle, and glutamate, which participates in nitrogen handling and neurotransmission, together helping to reduce ammonia accumulation that contributes to encephalopathy.
Is arginine glutamate safe to use?
In the cited trial, adverse events were comparable to the active comparator, with only a few drug‑related reactions reported. Long‑term safety and effects in broader patient groups have not been fully established.
Can arginine glutamate be taken orally?
Yes, the compound is listed as available for oral administration, although the clinical trial evidence pertains to intravenous infusion; oral use should follow prescribing guidance.
Are there benefits beyond liver disease?
Animal and mechanistic reviews suggest arginine and glutamate may support intestinal development in piglets and influence nitric‑oxide pathways in cardiovascular health, but human clinical data for these applications are currently lacking.
What is Arginine glutamate?
Arginine glutamate is an approved prescription amino‑acid salt composed of L‑arginine and L‑glutamate. It is supplied for intravenous or oral use and is investigated chiefly for supporting liver‑related metabolic disorders such as mild hepatic encephalopathy, where it may help lower blood ammonia and improve neurological function.
What is Arginine glutamate used for?
Arginine glutamate is educationally associated with: Nitrogen balance support, Liver protection / hepatoprotection, Hepatic encephalopathy management, Nitric oxide precursor support, Ammonia detoxification. Educational only — not medical advice.
How is Arginine glutamate administered?
Recorded routes of administration: Intravenous, Oral.
What are the potential side effects of Arginine glutamate?
Reported adverse effects include: Injection site reactions, Hypotension, Flushing, Nausea and vomiting, Hyperkalemia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Arginine glutamate?
Recorded contraindications: Severe renal failure, Severe metabolic alkalosis, Hyperargininemia, Known hypersensitivity to arginine or glutamate. Consult a qualified clinician before use.